RET-IN-23

SKU: orb1944343

Description

RET-IN-23 is a potent and orally bioavailable small molecule inhibitor targeting RET, demonstrating significant anti-tumor efficacy in non-small cell lung cancer (NSCLC) models. It is a valuable research tool for investigating RET-driven oncogenesis in both in vitro cellular assays and in vivo xenograft studies.

Research Area

Cell Biology, Signal Transduction

Key Properties

• CAS Number: 2479961-46-9
• MW: 537.59
• Purity: 97.46% (May vary between batches)
• Formula: C₂₈H₂₈FN₁₁
• SMILES: FC=1C=NN(C1)C2=NC=C(C=C2)CN3C4CN(C5=NC=C(C=C5)C6=NC(=CC(=N6)C)NC7=NNC(=C7)C)CC3C4
• Target: c-RET

Bioactivity

• Target IC50:
  RET (WT):1.32 nM|RET (CCDC6):2.50 nM|RET (M918T):1.47 nM|RET (V804L):6.54 nM|RET (V804M):1.03 nM
• In Vivo:
  RET-IN-23 exhibited significant antitumor activity in mice after oral administration at a dose of 5 mg/kg.
• In Vitro:
  RET-IN-23 is a potent and orally active RET inhibitor with IC50 of 1.32, 2.50, 6.54, 1.03, and 1.47 nM for RET-WT, RET-CCDC6, RET-V804L, RET-V804M, and RET-M918T, respectively.
  Read more...

Storage & Handling

• Storage: -20°C
• Expiration Date: 12 months from date of receipt.
• Disclaimer: For research use only

Compound Identifiers

PubChem CID

146013180